Cipla shares drop 2% after US FDA approves rival's generic Advair inhaler. Aurobindo Pharma's Lannett acquisition may raise US revenue by $30-40 million Cipla seeks FDA approval for generic Advair, ...

Asthma inhalers can be for quick relief or long-term control. Rescue inhalers work by relaxing your airway muscles to help you breathe better. People with chronic asthma may need a daily inhaler to ...

Inhalers can either be short-acting or long-acting, and they are used for different reasons. Combination inhalers contain two or three different drugs, like bronchodilators or a bronchodilator and a ...

Drugmaker Cipla continues to struggle with regulatory challenges which have caused delays in the launch of two key drugs--respiratory medication Advair and chemotherapy drug Abraxane- yet again. The ...

1. In this cohort study, using generic versus brand-name fluticasone-salmeterol was associated with similar outcomes in chronic obstructive pulmonary disease (COPD) patients. 2. Using generic versus ...

Advair (fluticasone propionate/salmeterol) and Symbicort (budesonide/formoterol) are brand-name prescription medications. They’re approved by the Food and Drug ...

Lannett has submitted an ANDA to the Food and Drug Administration for its strategic partner, Respirant's fluticasone propionate and salmeterol inhalation powder (100/50 mcg, 250/50 mcg and 500/50 mcg) ...

Lannett is seeking the approval of a generic form of Advair Diskus (fluticasone-salmeterol powder) in the U.S. Such an approval would be expected to provide a less-expensive alternative to the ...

PHILADELPHIA, April 1, 2021 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced the submission of an Abbreviated New Drug Application (ANDA) for Fluticasone propionate and Salmeterol ...

(Alliance News) - Hikma Pharmaceuticals PLC said late Thursday that it has received approval from the US Food & Drug Administration for its generic version of GlaxoSmithKline PLC's Advair Diskus drug.

(RTTNews) - Hikma Pharmaceuticals Plc (HIK, HIK.L) said it received a minor complete response letter or CRL from the US Food and Drug Administration or FDA in relation to its abbreviated new drug ...

MUMBAI, India, May 19, 2020 /PRNewswire/ -- Cipla Limited ((BSE: 500087) (NSE: CIPLA EQ) and hereafter referred to as "Cipla") today announced its submission of an Abbreviated New Drug Application ...